戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                Contralateral prophylactic mastectomy.
2 d incidental breast cancer detected during a prophylactic mastectomy.
3 t cancer; 4,969 patients chose contralateral prophylactic mastectomy.
4 terval cancers, and 25 cancers discovered at prophylactic mastectomy.
5   No cancers occurred in women who underwent prophylactic mastectomy.
6 rs expected in our cohort had they not had a prophylactic mastectomy.
7 mong their 403 sisters who had not undergone prophylactic mastectomy.
8 pected in these two groups in the absence of prophylactic mastectomy.
9 r include surveillance, chemoprevention, and prophylactic mastectomy.
10  to surgery, mastectomies, and contralateral prophylactic mastectomies.
11  Fifty-six patients (5%) underwent bilateral prophylactic mastectomy; 1,004 chose surveillance with (
12 nt at one year, 34 percent at five years) or prophylactic mastectomy (17.3 percent at one year, 30.4
13 of breast cancer who had undergone bilateral prophylactic mastectomy: 214 at high risk and 425 at mod
14 re diagnosed before the respective proband's prophylactic mastectomy, 38 were diagnosed afterward, an
15  Among 519 women who underwent contralateral prophylactic mastectomy, 86.5% were satisfied with their
16 as 75.9% including the cancers discovered at prophylactic mastectomy (95% confidence interval: 69.5%,
17 e mailed surveys to women with contralateral prophylactic mastectomy after breast cancer diagnosis be
18 rom 2.9 to 5.3 years of life expectancy from prophylactic mastectomy and from 0.3 to 1.7 years of lif
19 in two (1.9%) of 105 women who had bilateral prophylactic mastectomy and in 184 (48.7%) of 378 matche
20                                              Prophylactic mastectomy and oophorectomy are often consi
21 s for women with cancer, and the efficacy of prophylactic mastectomy and oophorectomy in preventing b
22  years for mutation carriers undergoing both prophylactic mastectomy and oophorectomy.
23          In a decision analysis, we compared prophylactic mastectomy and prophylactic oophorectomy wi
24                                              Prophylactic mastectomy and prophylactic oophorectomy, e
25  of these procedures, rates of contralateral prophylactic mastectomy and sentinel lymph node biopsy i
26 re mutation carriers who underwent bilateral prophylactic mastectomy and who were followed prospectiv
27 nd prophylactic oophorectomy, 3.5 years with prophylactic mastectomy, and 4.9 years with both surgeri
28 he data on the outcomes for surveillance and prophylactic mastectomy are incomplete.
29      We determined the rate of contralateral prophylactic mastectomy as a proportion of all surgicall
30 east cancer and elected to undergo bilateral prophylactic mastectomy at a large, tertiary US health c
31 irteen patients (9.6%) underwent a bilateral prophylactic mastectomy at a median of 23 months followi
32 ory of breast cancer who underwent bilateral prophylactic mastectomy at the Mayo Clinic between 1960
33 moprevention, and those undergoing bilateral prophylactic mastectomies between 1980 and 2009.
34 reast cancer on the basis of family history, prophylactic mastectomy can significantly reduce the inc
35    Breast cancers detected by imaging and/or prophylactic mastectomy compared with physical findings
36 y high among patients choosing contralateral prophylactic mastectomy, complications and procedure ext
37            The growing rate of contralateral prophylactic mastectomy (CPM) among women diagnosed as h
38 ision-making process regarding contralateral prophylactic mastectomy (CPM) among women with sporadic
39 ienced by patients who undergo contralateral prophylactic mastectomy (CPM) and breast reconstruction.
40 ne national temporal trends in contralateral prophylactic mastectomy (CPM) and determine whether surv
41  in BRCA1/2 genes) who opt for contralateral prophylactic mastectomy (CPM) have a substantially reduc
42 anslation BACKGROUND: Rates of contralateral prophylactic mastectomy (CPM) have increased dramaticall
43 e investigated the efficacy of contralateral prophylactic mastectomy (CPM) in reducing contralateral
44                                Contralateral prophylactic mastectomy (CPM) is one option for reducing
45                                Contralateral prophylactic mastectomy (CPM) rates in women with unilat
46         Guidelines assert that contralateral prophylactic mastectomy (CPM) should be discouraged in p
47 rcinoma in situ (DCIS) undergo contralateral prophylactic mastectomy (CPM) to prevent cancer in the o
48                                Contralateral prophylactic mastectomy (CPM) use is increasing among wo
49 ptions, such as mastectomy and contralateral prophylactic mastectomy (CPM).
50 he opposite uninvolved breast (contralateral prophylactic mastectomy [CPM]), although the risk of con
51                     The use of contralateral prophylactic mastectomies (CPMs) among patients with inv
52                    The rate of contralateral prophylactic mastectomies (CPMs) continues to rise, alth
53           Patients were excluded if they had prophylactic mastectomy; delayed reconstruction; mixed-t
54 rvention increased the cost-effectiveness of prophylactic mastectomy for BRCA1 mutation carriers to 7
55            Data on the efficacy of bilateral prophylactic mastectomy for breast cancer risk reduction
56 en having mastectomy, rates of contralateral prophylactic mastectomy have increased from less than 2%
57                     The use of contralateral prophylactic mastectomy in the United States more than d
58 etermine the use and trends of contralateral prophylactic mastectomy in the United States.
59 be reduced significantly after contralateral prophylactic mastectomy in women with a personal and fam
60 e use of medically unnecessary contralateral prophylactic mastectomy in women with nonhereditary, uni
61 dy suggests that positive outcomes following prophylactic mastectomy include decreased emotional conc
62                                              Prophylactic mastectomy is a preventive option for women
63 tation carriers with no history of bilateral prophylactic mastectomy matched to cases on gene, center
64 patients with negative MR findings underwent prophylactic mastectomy; no malignancy was found.
65 f life was not associated with contralateral prophylactic mastectomy or demographic characteristics,
66 old and had no previous history of bilateral prophylactic mastectomy or ovarian cancer, at least 2 mo
67 P < .001), and the increase was greatest for prophylactic mastectomy or therapeutic mastectomy for in
68 (OR, 1.73; 95% CI, 1.62-1.85), contralateral prophylactic mastectomy (OR, 1.48; 95% CI, 1.23-1.77), a
69 edical oncologists and surgeons to recommend prophylactic mastectomy (P < .001), as were physicians i
70 e imaging (MRI) from ages 25 to 69 years and prophylactic mastectomy (PM) and/or prophylactic oophore
71 ance imaging (MRI) from ages 25 to 69 years, prophylactic mastectomy (PM) at various ages, and/or pro
72 rophylactic surgery, our model suggests that prophylactic mastectomy provides substantial gains in li
73                  Likewise, the contralateral prophylactic mastectomy rate for patients undergoing mas
74 d during the study period, the contralateral prophylactic mastectomy rate increased.
75                                Contralateral prophylactic mastectomy rates increased from 5% to 12% o
76 n rates ranged from 3% to 62%, contralateral prophylactic mastectomy rates ranged from 9% to 67%, and
77 sociated with the decision for contralateral prophylactic mastectomy; rather, the clinical factors as
78                                    Bilateral prophylactic mastectomy reduced the risk of breast cance
79                                    Bilateral prophylactic mastectomy reduces the risk of breast cance
80          Most women undergoing contralateral prophylactic mastectomy report satisfaction with their d
81                                              Prophylactic mastectomy should be considered on an indiv
82                               None of the 84 prophylactic mastectomies showed nipple involvement by I
83 e incidental breast cancer was detected in a prophylactic mastectomy specimen.
84  when including and not including cancers in prophylactic mastectomy specimens, respectively).
85  investigated on breast tissues excised from prophylactic mastectomy specimens.
86 41 women with no history of breast cancer or prophylactic mastectomy, the incidence of breast cancer
87                                       Beyond prophylactic mastectomy, there are currently very few op
88 1.4% of physicians would recommend bilateral prophylactic mastectomy to a 38-year-old BRCA1 mutation
89                               Mean time from prophylactic mastectomy to last follow-up was 14.5 years
90  BRCA1-mutation carriers) frequently undergo prophylactic mastectomy to minimize their risk of breast
91 nilateral breast cancer choose contralateral prophylactic mastectomy to prevent cancer in the opposit
92                                Contralateral prophylactic mastectomy use is substantial among patient
93 ions for preference-based procedures such as prophylactic mastectomy vary by physician characteristic
94 ncer is reviewed to help guide the choice of prophylactic mastectomies vs breast-conserving therapy.
95                            The median age at prophylactic mastectomy was 42 years.
96                                        Thus, prophylactic mastectomy was associated with a reduction
97                                              Prophylactic mastectomy was observed to significantly re
98  have a mutation, would be likely to undergo prophylactic mastectomy, whereas 12% of nurse practition
99 arian cancer risk by 45%, and that bilateral prophylactic mastectomy would reduce breast cancer risk